Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01736943
Recruitment Status : Recruiting
First Posted : November 29, 2012
Last Update Posted : March 2, 2018
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
University of California, Davis

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2018
  Estimated Study Completion Date : December 2019